Darrell Tan

MD, FRCPC, PhD

Scientist

Biography

Dr. Darrell Tan is an infectious diseases physician, clinician-scientist and Canadian Institutes of Health Research (CIHR) New Investigator whose research focuses on clinical trials in human immunodeficiency virus (HIV) prevention and HIV/sexual transmitted infection (STI) co-infection. As Director of the University of Toronto Clinical Research Unit on HIV Prevention and co-leader of the CIHR Canadian HIV Trials Network Biomedical Prevention Working Group, he is leading multiple efforts to optimize the implementation of HIV pre- and post-exposure prophylaxis (PrEP and PEP) in Canada. These include Canada’s first demonstration project of daily oral TDF/FTC-based PrEP in Toronto MSM, the development of national Clinical Practice Guidelines on PEP & PrEP use, exploration of the relationship between syndemic health problems and clinical outcomes of PEP & PrEP, studies of nurse-led PEP & PrEP, and evaluations of novel antiretroviral PEP regimens.

Additional research interests are in the interaction between HIV and common co-infections such as herpes simplex virus type 2 (HSV-2) and syphilis, and the role of systemic inflammation in driving clinical outcomes in people living with HIV. He is also Co-Principle Investigator on two CIHR-supported multicentre randomized control trials including the a trial of anti-herpes medication for attenuating HIV disease progression, and a trial of enhanced syphilis screening in HIV-positive men.

Recent Publications

  1. Costiniuk, CT, Lee, T, Singer, J, Galipeau, Y, Arnold, C, Langlois, MA et al.. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study. Vaccines (Basel). 2024;12 (5):. doi: 10.3390/vaccines12050447. PubMed PMID:38793698 PubMed Central PMC11125718.
  2. Zhabokritsky, A, Klein, M, Loutfy, M, Guaraldi, G, Andany, N, Guillemi, S et al.. Non-AIDS-defining comorbidities impact health related quality of life among older adults living with HIV. Front Med (Lausanne). 2024;11 :1380731. doi: 10.3389/fmed.2024.1380731. PubMed PMID:38690177 PubMed Central PMC11058201.
  3. Halani, S, Tan, D, Andany, N. Long-acting injectable antiretroviral therapy for HIV-1 infection in adults. CMAJ. 2024;196 (10):E341-E342. doi: 10.1503/cmaj.231498. PubMed PMID:38499310 PubMed Central PMC10948187.
  4. Sinno, J, Daroya, E, Wells, A, Hull, M, Lachowsky, NJ, Tan, DHS et al.. "To do so in a patient-centred way is not particularly lucrative": The effects of neoliberal health care on PrEP implementation and delivery. Soc Sci Med. 2024;347 :116749. doi: 10.1016/j.socscimed.2024.116749. PubMed PMID:38492264 .
  5. Hart, TA, Noor, SW, Tavangar, F, Zahran, A, Skakoon-Sparling, S, Tan, DHS et al.. Human Immunodeficiency Virus Treatment Attitudes and Bacterial Sexually Transmitted Infections Among Gay and Bisexual Men. Sex Transm Dis. 2024;51 (3):178-185. doi: 10.1097/OLQ.0000000000001915. PubMed PMID:38412464 .
  6. Tan, DHS, Pico Espinosa, O, Matelski, J, Khera, SS, Qamar, A, Persaud, R et al.. Longitudinal Analysis of Mpox Virus DNA Detectability From Multiple Specimen Types During Acute Illness: A Cohort Study. Open Forum Infect Dis. 2024;11 (2):ofae073. doi: 10.1093/ofid/ofae073. PubMed PMID:38390463 PubMed Central PMC10883290.
  7. Sadeghi, Y, Nelson, P, Sullivan, A, Allen, V, Hasso, M, Liu, J et al.. Can laboratory HIV and infectious syphilis data inform future pre-exposure prophylaxis use in women in Ontario, Canada?. Sex Transm Infect. 2024;100 (3):184-186. doi: 10.1136/sextrans-2023-055985. PubMed PMID:38290811 PubMed Central PMC11041547.
  8. Lewin, A, Goldman, M, Busch, MP, Davison, K, van de Laar, T, Tiberghien, P et al.. End of selection criteria based on sexual orientation: An international symposium on alternatives to donation deferral. Vox Sang. 2024;119 (4):388-401. doi: 10.1111/vox.13587. PubMed PMID:38270352 .
  9. Sachdeva, H, Shahin, R, Ota, S, Isabel, S, Mangat, CS, Stuart, R et al.. Preparing for Mpox Resurgence: Surveillance Lessons From Outbreaks in Toronto, Canada. J Infect Dis. 2024;229 (Supplement_2):S305-S312. doi: 10.1093/infdis/jiad533. PubMed PMID:38035826 PubMed Central PMC10965211.
  10. Clifford Rashotte, M, Yoong, D, Naccarato, M, Pico Espinosa, OJ, Fisher, K, Bogoch, II et al.. Appropriate usage of post-exposure prophylaxis-in-pocket for HIV prevention by individuals with low-frequency exposures. Int J STD AIDS. 2024;35 (6):446-451. doi: 10.1177/09564624231215151. PubMed PMID:37963270 PubMed Central PMC11047008.
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, University of Toronto
  • Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto
  • Director, HIV Prevention Clinical Research Unit, University of Toronto
  • Affiliate Scientist, Toronto General Research Institute